Skip to main content
Clinical Trials/NCT05687552
NCT05687552
Not yet recruiting
Not Applicable

Role of 18F-FDG PET/CT in Gastric Cancer

Sohag University0 sites50 target enrollmentJanuary 2023
ConditionsGastric Cancer

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Gastric Cancer
Sponsor
Sohag University
Enrollment
50
Primary Endpoint
comparison of pet -ct finding with ct finding
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

The objective of the study is to assess the value of PET/CT in diagnosis, staging, response evaluation, and relapse monitoring of gastric cancer.

Detailed Description

gastric cancer (GC) is the fifth most common malignancy and the third leading cause of cancer mortality worldwide (1) It carries a poor prognosis, with a 5-year survival of only 20%-30% (2) Clinical staging, based mainly on imaging, is critical in determining the best treatment.There is a widely accepted consensus of the usefulness of FDG PET/CT in staging and restaging of gastric cancer. According to evidence-based data, this modality can evaluate gastric cancer more accurately and is helpful for evaluation of tumor biologic characteristics, detection of lymph node and distant metastases, assessment of tumor response to therapy(9). retrospective and prospective study will conducted at Sohag oncology hospital, nuclear medicine unit\& Assuit university hospital, nuclear medicine unit including 50 patients in 12 months .

Registry
clinicaltrials.gov
Start Date
January 2023
End Date
January 2024
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Sara Saber Ahmed

assisstant lecturer

Sohag University

Eligibility Criteria

Inclusion Criteria

  • patients diagnosed as GC on surgically resected specimens;
  • Patients with gastric and extragastric metastasis.
  • patients with gastric cancer either operated or not.

Exclusion Criteria

  • Patients with second malignancy.
  • Patient without proven pathology of cancer stomach.
  • Severely ill patient (patient with disturbed conscious level, or couldn't lay supine during the imaging).
  • uncontrolled diabetic patient with blood glucose level more than 200mg\\dl.
  • pregnant women

Outcomes

Primary Outcomes

comparison of pet -ct finding with ct finding

Time Frame: base line

The 18F-FDG PET/CT scan is visually estimated in the patients included in the study and quantitatively assessed by estimation of standardized uptake value(suv max). Statistical analysis of the included quantitative data.

Similar Trials